Combining previous results and those of the present study, a new therapeutic approach targeting CD133 and a practical application using CD133 in predicting the prognosis for GIST may be a promising new approach, however, further studies are necessary. The gene discussed is PROM1; the disease is gastrointestinal stromal tumor.